New combination therapy will be available on the NHS, offering new hope to people with advanced Hodgkin lymphoma ...

NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda.

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended brentuximab ...

A new treatment for Hodgkin lymphoma has been recommended for routine use on the NHS. Around 800 people with the advanced ...

A new treatment for Hodgkin lymphoma has been recommended for routine use on the NHS. Around 800 people with the advanced ...

It is estimated that about 800 people with Hodgkin lymphoma could benefit from the decision by the National Institute for Health and Care Excellence.

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or following ...

Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated ...

Genmab's Tivdak wins Japan's approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.

BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...